Erismodegib, also known as the compound LDE225, has captured the attention of the pharmaceutical and medical industry worldwide, due to recent and extremely successful study data. Conducted by Novartis, the reports from a Phase 2 study have shown Erismodegib to be a top-notch drug, eradicating basal cell carcinoma a number of patients. Dispensed as an oral treatment for patients suffering from advanced basal cell carcinoma, the study results easily met the primary endpoint, garnishing an objective response rate within six months’ time. The objective response was based on the criteria of the complete absence of advanced basal cell carcinoma, and clinically sizable tumor shrinkage. The pharmaceutical industry is poised for a potential earlier than planned FDA application from Novartis, based on these incredible Phase 2 results.
As an effectual drug that inhibits a receptor coined smoothened, that regulates the hedgehog signaling pathway, Erismodegib efficiently and safely blocks tumor growth. With basal cell carcinoma accounting for over 80 percent of non-melanoma cancers, treatments for advanced stages of this form of skin cancer are urgently needed. The advent of an easy to dispense oral treatment to fight this now common cancer worldwide offers hope for a greater number of patients. Around the world there is a 10 percent incident increase of basal cell carcinoma every year, which is likely due to an aging population and greater exposure to dangerous ultraviolet rays. Basal Cell Carcinoma does not often metastasize, but more advanced cases of this regularly seen disease are manifesting. The exciting data gleaned from Novartis’s study of Erismodegib showcasing patients who achieved complete remission is nothing short of miraculous.
LGM Pharma provides Erismodegib CAS# 956697-53-3, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.